Merck (MRK) closed the most recent trading day at $126.15, moving -0.47% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 0.74%. Elsewhere, the Dow lost 0.01%, while the tech-heavy Nasdaq added 1.68%.The pharmaceutical company's stock has climbed by 3.76% in the past month, exceeding the Medical sector's loss of 4.72% and the S&P 500's gain of 0.8%.Investors will be eagerly watching for the performance of Merck in its upcoming earnings disclosure. The compan ...

Merck (MRK) announced that a phase II/III study has been initiated on its CDH6-directed DXd antibody-drug conjugate, raludotatug deruxtecan (R-DXd), in patients with platinum-resistant ovarian cancer. The first patient has been dosed in the phase II/III study called REJOICE-Ovarian01. Merck is developing R-DXd in partnership with Japan’s Daiichi Sankyo.The initiation of the REJOICE-Ovarian01 study is based on data from the ongoing phase I study in which R-DXd showed promising activity in patients with advan ...

Merck (MRK) closed at $127.99 in the latest trading session, marking a +0.26% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 1.11%. Meanwhile, the Dow gained 0.8%, and the Nasdaq, a tech-heavy index, added 1.24%.The pharmaceutical company's shares have seen an increase of 2.96% over the last month, surpassing the Medical sector's loss of 2.46% and the S&P 500's gain of 0.48%.The investment community will be closely monitoring the performance of Merck in its forthcomi ...

Merck (MRK) has initiated phase III study on its oral KRAS G12C inhibitor candidate, MK-1084, for first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC).The study will evaluate MK-1084 in combination with Merck’s blockbuster PD-L1 inhibitor Keytruda in patients with metastatic NSCLC whose tumors harbor KRAS G12C mutations and express PD-L1 (tumor proportion score [TPS] ≥50%). In some early studies, MK-1084, in combination with Keytruda, has demonstrated some promising an ...

Merck (MRK) announced that a phase II/III study has been initiated on its CDH6-directed DXd antibody-drug conjugate, raludotatug deruxtecan (R-DXd), in patients with platinum-resistant ovarian cancer. The first patient has been dosed in the phase II/III study called REJOICE-Ovarian01. Merck is developing R-DXd in partnership with Japan’s Daiichi Sankyo.The initiation of the REJOICE-Ovarian01 study is based on data from the ongoing phase I study in which R-DXd showed promising activity in patients with advan ...

Sundry Photography One of the biggest pharmaceutical stocks by market capitalization, Merck & Co., Inc. (NYSE:MRK) has had a good first quarter at the stock markets in 2024. Its price is up by over 20% after a forgettable 2023 that saw it end the year essentially flat, supported by approvals for its treatments as well as its final quarter (Q4 2023) and full-year 2023 results. Supportive fundamentals might be a necessary condition for a stock’s consistent success in the markets, but they aren’t sufficien ...

GERMANY - 2024/02/16: In this photo illustration, a Pfizer, Inc. logo seen displayed on a tablet. ... [+] (Photo Illustration by Igor Golovnov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesGiven its attractive valuation, we believe Pfizer stock (NYSE: PFE) is a better pick than its peer — Merck stock (NYSE: MRK). MRK trades at a higher valuation multiple of 5.6x revenues vs. 2.7x for PFE, due to its superior revenue growth over the last year and a better financial position ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Scores?The Z ...

Merck (MRK) announced that the phase III KEYLYNK-006 study, evaluating the combination of its blockbuster drugs Keytruda and Lynparza in certain non-small cell lung cancer (NSCLC) patients, failed to meet its primary endpoints.The KEYLYNK-006 study evaluated Keytruda, combined with Lynparza as maintenance therapy, for the first-line treatment for patients with metastatic non-squamous NSCLC with no EGFR, ALK or ROS1 genomic tumor aberrations. Patients in the control group received pemetrexed chemotherapy ins ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive data from multiple Phase 3 studies evaluating V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the 13th Meeting of the International Society of Pneumonia and Pneumococcal Diseases (ISPPD) in Cape Town, South Africa. Across the clinical studies presented, V116 was shown to be immunogenic for all 21 serotypes covered by the vaccine in ...